Lipophilicity and Hydrophobicity

Lipophilicity is a molecule's tendency to partition into a non-polar (lipid-like) environment rather than water, and it is one of the single most influential physicochemical properties in medicinal chemistry. It governs how a drug crosses membranes, binds to its target, and is metabolised and cleared, which is why it sits at the centre of structure-activity reasoning.

Definition

Lipophilicity is the affinity of a compound for a lipophilic (non-polar) phase relative to an aqueous phase, most commonly quantified by the logarithm of the octanol-water partition coefficient (log P) for the neutral species, or the distribution coefficient (log D) at a stated pH for ionisable compounds.

Scope

The entry covers how lipophilicity is defined and measured (partition and distribution coefficients), the hydrophobic effect that drives it, the role it plays in absorption, binding, and clearance, and the property-based design rules that constrain it. It treats lipophilicity as a physicochemical determinant of activity, not as clinical advice.

Core questions

• How is lipophilicity defined and measured, and how do log P and log D differ?
• Why does the hydrophobic effect drive partitioning and binding?
• How does lipophilicity influence membrane permeability, target binding, solubility, and metabolic clearance?
• What range of lipophilicity is associated with favourable drug-like behaviour, and why?

Key concepts

• Partition coefficient (log P)
• Distribution coefficient (log D) and pH dependence
• Octanol-water reference system
• Hydrophobic effect
• Membrane permeability
• Aqueous solubility trade-off
• Lipophilic efficiency (LipE/LLE)
• Rule-of-five lipophilicity limit

Key theories

Hydrophobic parameter in quantitative SAR

Within a congeneric series, biological activity often correlates with a hydrophobic substituent parameter derived from partition coefficients, so lipophilicity can be treated as a quantitative, additive contributor to activity in linear free-energy (Hansch) analysis.

Mechanisms

The hydrophobic effect — the entropically favourable release of ordered water molecules when non-polar surfaces are removed from contact with water — drives a lipophilic molecule to partition into lipid phases and to bury non-polar surface against a binding site. This same property governs passive diffusion across lipid bilayers, so moderate lipophilicity tends to favour membrane permeability, while excessive lipophilicity reduces aqueous solubility, increases binding to off-target sites and plasma proteins, and raises susceptibility to oxidative metabolism. Lipophilicity is quantified by partitioning a compound between octanol and water (log P for the neutral form) or, for ionisable molecules, by the pH-dependent distribution coefficient log D. Because activity gained simply by adding lipophilicity is often non-specific, chemists track lipophilic efficiency to favour potency that arises from specific interactions rather than bulk hydrophobicity.

Clinical relevance

Lipophilicity helps explain why otherwise similar drugs differ in absorption, tissue distribution, and clearance, and why pushing potency through added lipophilicity can worsen solubility, off-target binding, and metabolic stability. The content is educational background on a physicochemical property and its role in drug behaviour, not guidance for dosing or individual treatment.

Evidence & guidelines

The understanding of lipophilicity rests on foundational physical-organic and medicinal-chemistry literature — the compilation and use of partition coefficients by Leo and Hansch, their incorporation into quantitative SAR, and later property-based heuristics such as Lipinski's rule of five and analyses of lipophilicity's influence on design decisions. These are methodological design principles rather than clinical guidelines.

History

Partition coefficients moved from physical chemistry into drug design in the 1960s and 1970s, when Hansch and Fujita showed that a hydrophobic parameter derived from octanol-water partitioning could correlate with biological activity, and Leo and Hansch systematically compiled and rationalised partition data. By 2001 lipophilicity had become a pillar of property-based design through Lipinski's rule of five, and later reviews documented its pervasive, sometimes problematic, influence on medicinal-chemistry decision-making.

Debates

Is creeping lipophilicity inflating drug-candidate properties?

Analyses have argued that medicinal chemists tend to raise lipophilicity and molecular weight when optimising potency, degrading solubility and selectivity; efficiency metrics that normalise potency for lipophilicity were proposed to counter this drift, though how strictly to apply such limits is debated.

Key figures

• Corwin Hansch
• Albert Leo
• Toshio Fujita
• Christopher Lipinski
• Paul Leeson

Seminal works

• leo-hansch-1971
• hansch-fujita-1964
• lipinski-2001

Frequently asked questions

What is the difference between log P and log D?

Log P is the partition coefficient of the neutral form of a compound between octanol and water; log D is the distribution coefficient at a specified pH that accounts for the ionised fraction as well, so for ionisable drugs log D varies with pH while log P does not.

Why does too much lipophilicity cause problems in drug design?

High lipophilicity tends to lower aqueous solubility, increase non-specific and off-target binding, raise plasma-protein binding, and make a molecule more vulnerable to metabolic oxidation, so potency gained purely by adding lipophilicity often comes with liabilities.